Weill Cornell Breast Center: List of Open Clinical Trials

Below is a complete list of open clinical trials at the Weill Cornell Breast Center. Click on the study name to read detailed information about the study. To find out more about our clinical trials or to make an appointment at the Breast Center, please call (212) 821-0644.

Supportive Care/Non-Treatment Studies

Study Name Goal of Study Eligibility
Cold Cap Study Preventing hair-loss using the Cold Cap during Taxotere/Cytoxan (TC) -Early Stage Breast Cancer-Begins with TC chemotherapy
Glutamine Study Reducing peripheral neuropathy using glutamine -Grade 1 or above neuropathy-During or after Taxol or Abraxane.
Herceptin Cardiotoxicity Evaluating variations in DNA sequencing (SNPs) on risk of Herceptin-related heart failure -Congestive heart failure-Decline in ejection fraction by 15%
Rakhi Study To study how breast tumors develop blood vessels -Blood samples during treatment-Already underwent surgery

Treatment Studies

Study Name Goal of Study Eligibility
GALENA A vaccine trial: evaluating NeuVax in preventing breast cancer recurrence. -HER2 1+/2+, node positive-Completed standard treatment with surgery, chemo, radiation.
PUMA To study the benefit of two new drugs: Temsirolimus plus Neratinib in metastatic HER2 or TNBC* -No more than 4 prior chemo regimen-Received Herceptin in the past-No concurrent use of hormone therapy
RxSPONDER To study how hormone therapy work with or without chemotherapy in breast cancer -Hormone Positive, HER2 negative-Oncotype <25, 1-3 lymph node positive
BEACON New generation TOPO1 inhibitor NKTR-102 (targets tumor DNA) in recurrent or metastatic breast cancer -Already received 2-5 prior regimens-Already received Taxane, anthracycline, Xeloda, Herceptin (if HER2 +), and hormone therapy (if ER+)
IMMU-132 To study the effectiveness of antibody RS7 attached to SN38, a metabolite of Irinotecan -Already received 1-3 prior regimens-Active disease on CT or MRI
OPTIMER Immunotherapy with OPT-822 in metastatic breast cancer -Stable disease, partial response, or complete response after 1 regimen
ALLIANCE Using Panobinostat (blocks enzymes needed for cell growth) and Letrozole in TNBC* -TNBC* with metastatic disease
177-J591 Using an antibody J591 linked to radioactive molecule 177Lu, to target tumor blood vessels -Metastatic breast cancer-Already received standard therapy
SYNTA Using Ganetespib, a small molecule inhibitor against Hsp90 protein, to stop tumor growth -Previously untreated metastatic, HER2 positive, or TNBC*.
LUX-Breast 1 Using Afatinib (inhibits growth factor receptor) plus Navelbine vs. Herceptin plus Navelbine to stop tumor growth -HER2 positive, metastatic disease-Failed one prior treatment-No prior Navelbine
BKM120 Using BKM120 (inhibit tumor growth and survival by blocking PI3K pathway) with fulvestrant, to enhance cancer cell death -Metastatic, Hormone positive-HER2 negative-Progressed on or after aromatase inhibitor
NCI8264 Using PARP inhibitor ABT-888 (interfere with tumor DNA repair) alone or with Carboplatin -Metastatic BRCA-associated breast cancer
TM Using TM (copper depletion) to prevent recurrence in moderate to high risk patients -Metastatic no active disease-Stage 2 and above TNBC*.

*TNBC = Triple Negative Breast Cancer

What’s New in Metastatic Breast Cancer: Dr. Moore and Dr. Vahdat’s Presentations

This slideshow requires JavaScript.

At a seminar on June 21, 2012,  Dr. Anne Moore, Medical Director of the Weill Cornell Breast Center, and Dr. Linda Vahdat, Director of Research at the Breast Center, reported on the most promising and exciting news from the recent ASCO conference for those living with metastatic breast cancer.

Click below to view the slides from Dr. Moore’s and Dr. Vahdat’s presentations.


Report from ASCO Seminar: What’s New in Metastatic Breast Cancer?

A seminar with Dr. Anne Moore, Dr. Linda Vahdat and SHARE (Self-Help for Women with Breast or Ovarian Cancer)

Oncologists from around the globe share the newest discoveries in cancer research at “Collaborating to Conquer Cancer,” the annual meeting of the American Society of Clinical Oncology (ASCO) at the beginning of June 2012.

The Breast Center’s Dr. Anne Moore and Dr. Linda Vahdat will report on the highlights of ASCO, consolidating the most promising and exciting news into information that is meaningful for those living with metastatic breast cancer. Dr. Moore and Dr. Vahdat are actively involved in breast cancer research at the national and local level.

Dr. Moore is the Medical Director of the Weill Cornell Breast Center.
She is a Professor of Clinical Medicine at the Weill Medical College and Attending Physician at The New York Presbyterian Hospital.

Dr. Vahdat is a Professor of Medicine, Weill Cornell Medical College and
Director of Research at the Breast Center.

When

Thursday June 21, 6pm to 7:30 pm

Where

Weill Greenberg Conference Center
1305 York Avenue at 70th Street, Room B & C

REFRESHMENTS PROVIDED

To register or for more information call (212) 719-2943 or e-mail rsvp@sharecancersupport.org